Current therapies and new strategies for the management of Alzheimer's disease. (Q37770005)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

review article

1 reference

title

Current therapies and new strategies for the management of Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Olapeju G Aderinwale

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

Hans W Ernst

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

English

0 references

publication date

2 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

American Journal of Alzheimer's Disease & Other Dementias

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

414-424

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

Alzheimer disease: time to improve its diagnosis and treatment

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Current concepts in Alzheimer's disease: a multidisciplinary review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The spectrum of medical illness and medication use among residents of assisted living facilities in central Maryland

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The role of tau phosphorylation and cleavage in neuronal cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Long-term function in an older cohort--the cardiovascular health study all stars study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

beta-Amyloid is associated with reduced cognitive function in healthy older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Apolipoprotein E genotype and lifetime cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Apolipoprotein E, amyloid, and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Alzheimer's Disease in Adults with Down Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Current and future therapy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Cholinesterases and the Pathology of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The New Cholinesterase Inhibitors for Alzheimer's Disease, Part 2: Illustrating Their Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Memantine: a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Alternative Abeta immunotherapy approaches for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Perispinal etanercept: potential as an Alzheimer therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Perispinal Etanercept for Treatment of Alzheimers Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Dietary patterns associated with Alzheimer's disease: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1533317510372372

21 January 2018

Identifiers

DOI

10.1177/1533317510372372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20601643 AND SRC:MED&resulttype=core&format=json

7 February 2020

1 reference